Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Palatin Raises $22.7M For Drug Trials Via Stock, Warrants Sale

Feb. 2, 2004

By Aaron Lorenzo

Chiron Earnings Rise Due To Vaccine, Other Product Growth

Jan. 30, 2004

By Aaron Lorenzo

Chiron Earnings Rise Due To Vaccine, Other Product Growth

Jan. 30, 2004

By Aaron Lorenzo

Genelabs Licenses Out Japanese Prestara Rights For Up To $12M

Jan. 29, 2004

By Aaron Lorenzo

Genelabs Licenses Out Japanese Prestara Rights For Up To $12M

Jan. 29, 2004

By Aaron Lorenzo

Sirna Agrees To RNAi Cancer Drug Collaboration With Lilly

Jan. 28, 2004

By Aaron Lorenzo

Sirna Agrees To RNAi Cancer Drug Collaboration With Lilly

Jan. 28, 2004

By Aaron Lorenzo

Northfield To Support PolyHeme Pivotal Trial With $15M Financing

Jan. 27, 2004

By Aaron Lorenzo

Blood substitute developer Northfield Laboratories Inc. topped off the tank with $15 million in financing to fund a pivotal trial of its lead product, PolyHeme. (BioWorld Today)

Northfield To Support PolyHeme Pivotal Trial With $15M Financing

Jan. 27, 2004

By Aaron Lorenzo

Blood substitute developer Northfield Laboratories Inc. topped off the tank with $15 million in financing to fund a pivotal trial of its lead product, PolyHeme. (BioWorld Today)

AEterna, Zentaris Enter Another LHRH Product Deal With Solvay

Jan. 26, 2004

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...